ROCKVILLE, Maryland, February 19 /PRNewswire/ --
Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an exclusive distribution agreement with MedImmune for Ethyol(R) (amifostine). The agreement, which is scheduled to take effect on June 1, 2008, grants Pinnacle Biologics exclusive Ethyol marketing authorization, certain licenses and distribution rights in Western Europe, Turkey and Israel. Additional terms of the agreement were not disclosed.